التفاصيل البيبلوغرافية
| العنوان: |
Sunitinib in a MEN-1 Patient with Small Cell Neuroendocrine Tumor of the Thymus. |
| المؤلفون: |
Palmieri, G., Buonerba, C., Formisano, L., Damiano, V., Nappi, L., Federico, P., Colao, A., Matano, E., Faggiano, A., De Placido, S. |
| المصدر: |
Neuroendocrinology; Jul2012 Supplement, Vol. 96, p11-12, 2p |
| مصطلحات موضوعية: |
ONCOGENES, CANCER genes, MENIN, HYPERPARATHYROIDISM, ISLET cell tumor, CANCER treatment |
| مستخلص: |
Introduction: MEN-1 is an autosomal dominant disease caused by mutation of the oncosuppressor gene menin. MEN-1 is typically associated with hyperparathyroidism, islet cell tumors and pituitary adenomas, but it can also be associated with other neoplasms, such as thymic carcinoids. Aim(s): In January 2009, a 49-year old patient diagnosed with a small cell neuroendocrine tumor of the thymus, considered inoperable. From March 2009 to March 2011, she received several systemic anti-neoplastic therapy consisting of carboplatin-etoposide, capecitabine-gemcitabine, somatostatin analogues and Everolimus. In March 2011, the patient presented progressive radiographic disease with worsening of the mediastinal syndrome. In April 2011, she was started on Sunitinib as reported in a large phase III trial on neuroendocrine tumors of the pancreas. She quickly achieved symptomatic improvement. Stable disease was detected on PET-CT scan in July 2011, which was confirmed in December 2011 by PET-CT scan. Materials and methods: Sunitinib 50 mg/daily, 4/2 w. Results: Thymic carcinoids are described in about 8% of pts with MEN-1, while 25% of patients with thymic carcinoids have MEN-1. Prophylactic thymectomy is a reasonable approach for patients with MEN-1. Recently, both Everolimus and Sunitinib have proved to be effective in two randomized controlled trials in PNET, with a considerable extension of PFS. Conclusion: This is the first reported case of a patient with a small cell neuroendocrine tumor of the thymus treated with Sunitinib. [ABSTRACT FROM AUTHOR] |
|
Copyright of Neuroendocrinology is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
